{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:04:58Z","timestamp":1747181098593,"version":"3.40.5"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,13]]},"abstract":"<jats:p>The aim of this study was to compare the capability of different dual time (interval 1, 2, 3, or 4 hours) 18F-fluorodeoxyglucose (<jats:sup>18<\/jats:sup>F-FDG) positron emission tomography\/computed tomography (PET\/CT) with forced diuresis to diagnose prostate cancer (PCa). A retrospective review of 273 male patients from March 2009 to June 2019, with any focal <jats:sup>18<\/jats:sup>F-FDG uptake in the prostate gland during PET\/CT imaging. Early PET\/CT imaging was performed 60 minutes after FDG injection. Delayed imaging was performed 1 to 4 hours after diuretic injection. For prostate lesions with increased <jats:sup>18<\/jats:sup>F-FDG uptake, a spheroid-shaped volume of interest was drawn, including the entire lesion, and the maximum standard uptake value (SUVmax) of the lesion was measured. The SUVmax &gt; 2.5 after delayed imaging and the retention index &gt; 15% were used as the diagnostic criteria for PET\/CT in the diagnosis of PCa. Otherwise, it was diagnosed as the benign prostate disease. The final diagnosis was based on histological examination, associated imaging studies, or\/and clinical follow-up. The results of inter-group comparison showed that the SUVmax of 1-, 2-, 3-, and 4-hour delayed imaging after diuresis in PCa group was significantly higher than that in control group (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05), but there was no statistical difference in SUVmax of early imaging between PCa and control group (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; .05). And the retention index of PCa group that delayed 1, 2, 3, and 4 hours after diuresis were significantly higher than those of control group, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05). The diagnostic sensitivity of imaging delayed 1, 2, 3, and 4 hours after diuresis was 68.8%, 81.2%, 85.7 %, and 71.4%, the specificity was 52.5%, 74.5%, 70.6%, and 65.0%, and the accuracy was respectively 58.2%, 77.4%, 76.4%, and 67.6%, the positive predictive values were 44.0%, 68.9%, 64.3%, and 58.8%, and the negative predictive value were 75.6%, 85.4%, 88.9%, and 76.5%, respectively. <jats:sup>18<\/jats:sup>F-FDG PET\/CT imaging as an imaging tool lacks certain specificity in the diagnosis of PCa, regardless of whether the imaging is delayed. The main advantage of delayed diuretic imaging in PCa is that it can significantly improve the sensitivity, especially the diagnostic effect delayed 2 hours after diuresis is better.<\/jats:p>","DOI":"10.1097\/md.0000000000032331","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:55:49Z","timestamp":1673657749000},"page":"e32331","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of 18F-FDG PET\/CT imaging with different dual time 18F-FDG PET\/CT with forced diuresis in clinical diagnosis of prostate cancer"],"prefix":"10.1097","volume":"102","author":[{"given":"Longhua","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Hospital 971 of The Navy of Chinese PLA, Qingdao, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiming","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Pingjin Hospital, Characteristic Medical Center of Chinese People\u2019s Armed Police Forces, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of obstetrics and gynecology, Pingjin Hospital, Characteristic Medical Center of Chinese People\u2019s Armed Police Forces, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlan","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Pingjin Hospital, Characteristic Medical Center of Chinese People\u2019s Armed Police Forces, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Pingjin Hospital, Characteristic Medical Center of Chinese People\u2019s Armed Police Forces, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4106-943X","authenticated-orcid":false,"given":"Zhichun","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Pingjin Hospital, Characteristic Medical Center of Chinese People\u2019s Armed Police Forces, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer.","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening.","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-020-0332-z","article-title":"All change in the prostate cancer diagnostic pathway.","volume":"17","author":"Lomas","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/S1470-2045(20)30558-1","article-title":"Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit.","volume":"22","author":"Aggarwal","year":"2021","journal-title":"Lancet Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-020-04967-9","article-title":"The value of (18)F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.","volume":"48","author":"Ayati","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2967\/jnumed.118.223263","article-title":"Prediction of time to hormonal treatment failure in metastatic castration-sensitive prostate cancer with (18)F-FDG PET\/CT.","volume":"60","author":"Jadvar","year":"2019","journal-title":"J Nucl Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e8832","DOI":"10.1097\/MD.0000000000008832","article-title":"Role of delayed-time-point imaging during abdominal and pelvic cancer screening using FDG-PET\/CT in the general population.","volume":"96","author":"Naganawa","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MNM.0b013e3282f4d389","article-title":"Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan.","volume":"29","author":"Chen","year":"2008","journal-title":"Nucl Med Commun"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JU.0000000000001375","article-title":"Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART I.","volume":"205","author":"Lowrance","year":"2021","journal-title":"J Urol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/cncr.31337","article-title":"PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.","volume":"124","author":"Kearns","year":"2018","journal-title":"Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2478\/v10019-011-0026-3","article-title":"A comparison of virtual touch tissue quantification and digital rectal examination for discrimination between prostate cancer and benign prostatic hyperplasia.","volume":"46","author":"Zheng","year":"2012","journal-title":"Radiol Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis.","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bju.15134","article-title":"Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET\/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.","volume":"127","author":"Franklin","year":"2021","journal-title":"BJU Int"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/RLU.0000000000002526","article-title":"Comparing the staging\/restaging performance of 68ga-labeled prostate-specific membrane antigen and 18F-choline PET\/CT in prostate cancer: a systematic review and meta-analysis.","volume":"44","author":"Lin","year":"2019","journal-title":"Clin Nucl Med"},{"key":"R15-20250504","first-page":"5360","article-title":"Detection rate of 18F-choline positron emission tomography\/computed tomography in patients with non-metastatic hormone sensitive and castrate resistant prostate cancer.","volume":"13","author":"Zattoni","year":"2021","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00345-020-03344-3","article-title":"Novel PET imaging methods for prostate cancer.","volume":"39","author":"Mena","year":"2021","journal-title":"World J Urol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"299","DOI":"10.23736\/S1824-4785.18.03065-0","article-title":"Evaluation of physiologic and abnormal glucose uptake in palatine tonsils: differential diagnostics with sequential dual-time-point 2-deoxy-2-[18F]FDG PET\/CT.","volume":"64","author":"Pietrzak","year":"2020","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R18-20250504","first-page":"214","article-title":"Dual phase 18F-fluorodeoxyglucose positron emission tomography\/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer.","volume":"32","author":"Yildirim-Poyraz","year":"2013","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"R19-20250504","first-page":"155","article-title":"Diagnostic accuracy of visual analysis versus dual time-point imaging with (18)F-FDG PET\/CT for the characterization of indeterminate pulmonary nodules with low uptake.","volume":"40","author":"Grisanti","year":"2021","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00261-019-02396-3","article-title":"The added value of dual-time-point 18F-FDG PET\/CT imaging in the diagnosis of colorectal cancer liver metastases.","volume":"45","author":"Mao","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s12149-021-01671-y","article-title":"Comparison between dynamic whole-body FDG-PET and early-delayed imaging for the assessment of motion in focal uptake in colorectal area.","volume":"35","author":"Kotani","year":"2021","journal-title":"Ann Nucl Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1148\/radiol.2019190032","article-title":"Delayed (18)F FDG PET\/CT imaging in the assessment of residual tumors after transurethral resection of bladder cancer.","volume":"293","author":"Yan","year":"2019","journal-title":"Radiology"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.semnuclmed.2017.02.009","article-title":"Dual-time point (18)F-FDG-PET and PET\/CT for differentiating benign from malignant musculoskeletal lesions: opportunities and limitations.","volume":"47","author":"Parghane","year":"2017","journal-title":"Semin Nucl Med"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12149-013-0797-2","article-title":"Detection of colorectal cancer and adenomas by FDG-PET cancer screening program: results based on a nationwide Japanese survey.","volume":"28","author":"Minamimoto","year":"2014","journal-title":"Ann Nucl Med"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13139-013-0247-z","article-title":"The clinical role of dual-time-point (18)F-FDG PET\/CT in differential diagnosis of the thyroid incidentaloma.","volume":"48","author":"Lee","year":"2014","journal-title":"Nucl Med Mol Imaging"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/RLU.0b013e3182173823","article-title":"Impact of dual-time-point F-18 FDG PET\/CT in the assessment of pleural effusion in patients with non-small-cell lung cancer.","volume":"36","author":"Alkhawaldeh","year":"2011","journal-title":"Clin Nucl Med"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1186\/s13104-018-3985-2","article-title":"A prospective study on dual time (18)F-FDG-PET\/CT in high-risk prostate cancer patients.","volume":"11","author":"Mortensen","year":"2018","journal-title":"BMC Res Notes"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00259-013-2343-9","article-title":"When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?","volume":"40","author":"Cheng","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41391-020-0202-x","article-title":"GLUT1 expression in high-risk prostate cancer: correlation with (18)F-FDG-PET\/CT and clinical outcome.","volume":"23","author":"Meziou","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13550-017-0272-5","article-title":"Effective dose estimation for oncological and neurological PET\/CT procedures.","volume":"7","author":"Mart\u00ed-Climent","year":"2017","journal-title":"EJNMMI Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:38:34Z","timestamp":1746326314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032331","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}